Best Peptides for Mitochondrial Dysfunction & Cellular Energy: What the Evidence Actually Shows

Elamipretide is the strongest candidate here by a wide margin and the only peptide with direct human evidence that it improves cellular energy production. In a randomized, double-blind, placebo-controlled trial in 39 healthy older adults (ages 60–85) selected specifically for impaired in-vivo muscle mitochondrial energetics, a single two-hour IV infusion raised the maximal rate of ATP production (ATPmax) by roughly 27% versus about 12% with placebo, immediately post-infusion — the first demonstration that a drug can acutely reverse mitochondrial dysfunction in living human muscle. But mitochondrial coupling (P/O) did not change, fatigue resistance did not significantly improve, and the ATPmax effect had faded by day 7, consistent with the drug's short half-life. Its broader clinical record is mixed-to-negative: across four large randomized trials — MMPOWER-3 in primary mitochondrial myopathy, PROGRESS-HF in heart failure, EMBRACE-STEMI in acute MI, and ReCLAIM-2 in dry AMD — it missed every primary endpoint despite an elegant mechanism. Its one regulatory success is Barth syndrome, where the FDA granted accelerated approval as Forzinity in September 2025 based on a small open-label strength signal. Elamipretide works by crossing into mitochondria, binding cardiolipin, and stabilizing cristae and the electron transport chain. The preclinical case in aged mice is strong (restored ATPmax, coupling and exercise tolerance), but the human energy result is acute, reversible and surrogate-level. Grade B for cellular energy; Grade A only for the approved Barth indication; Grade C–D for general 'mitochondrial optimization.'

Best for

Understanding the ceiling of the evidence — the one peptide that measurably moved human cellular energy, yet only acutely and without a fatigue benefit

Pricing

Prescription (Forzinity, Barth only); no legitimate energy pathway

Source: Roshanravan et al., PLOS ONE 2021 (PMC8282018)

MOTS-c is the most clinically advanced of the mitochondrial-derived peptides and the one with the most striking exercise-capacity preclinical data — but its human efficacy for cellular energy remains essentially unproven. It is a 16-amino-acid peptide encoded within mitochondrial DNA that inhibits the folate cycle, driving accumulation of AICAR and activation of AMPK, the master cellular energy sensor, without first depleting ATP. This positions it as an 'exercise mimetic' signal. In animals the data are genuinely impressive: intermittent MOTS-c enhanced physical performance across young, middle-aged and old mice, and late-life treatment roughly doubled treadmill running capacity in old mice, who outran untreated middle-aged controls. Earlier work showed improved insulin sensitivity, glucose tolerance and AMPK/GLUT4 activation in skeletal muscle. But the human data are thin and indirect: circulating MOTS-c declines with age and is lower in diabetes and obesity (association, not efficacy); exercise itself induces roughly a 12-fold rise in muscle MOTS-c, meaning it is a mediator of exercise benefit rather than proof that injecting it helps; and the synthetic analog CB4211 completed a small Phase 1a/1b for NASH/obesity on metabolic endpoints before the program was discontinued. The first dedicated Phase 2a RCT of native MOTS-c (NCT07505745) only began recruiting in February 2026, targets insulin sensitivity rather than ATP output, and has no results. Every efficacy claim for mitochondrial energy is therefore Grade C (preclinical). MOTS-c is also banned by WADA at all times as an AMPK activator (S4.4.1), with no therapeutic-use exemption. The honest functional takeaway: MOTS-c is largely a marker and mediator of actual exercise — the durable way to raise it today is to train.

Best for

Understanding the most promising preclinical energy candidate — and why 'exercise in a vial' is still rodent biology, not human proof

Pricing

No approved product; 'research-use-only' material is unapproved/unverified

Source: Reynolds et al., Nat Commun 2021

Humanin is the founding mitochondrial-derived peptide — a legitimate endogenous cytoprotective and longevity signal — but it has zero interventional human evidence and a real oncologic safety caveat. It is a 24-amino-acid peptide encoded in the 16S rRNA region of mitochondrial DNA that signals back to the cell and nucleus. There has never been a Phase 1/2 or RCT of exogenous humanin or its potent S14G analog (HNG) in humans, so there is no human efficacy, pharmacokinetic or safety profile. Its human footprint is purely observational: circulating humanin declines with age, is higher and more sustained in children of centenarians, and a mitochondrial SNP associated with about 15% lower humanin tracks with faster cognitive aging in a large cohort. These are correlations, not proof that administering humanin benefits anyone — and a hemodialysis cohort found a U-shaped risk, with both very low and very high humanin associated with worse outcomes, arguing against a naive 'more is better' view. Preclinically the biology is strong: humanin rescues neurons from amyloid-β toxicity, blocks BAX/tBID-mediated apoptosis, and signals through a gp130/STAT3–AKT–ERK survival axis; HNG improves insulin sensitivity and protects the heart in rodents. But an important negative: in the pivotal mouse healthspan experiment, midlife HNG did not significantly extend lifespan, and humanin's biology is more cytoprotective and anti-apoptotic than directly energy-generating — it preserves mitochondria under stress rather than boosting ATP output per se. The principal safety concern is tumor promotion: humanin's pro-survival biology protected triple-negative breast-cancer and glioblastoma cells from apoptosis and blunted chemotherapy in animal models. Grade C for cellular energy — a real signal with promising biology and intriguing human correlations, but no interventional human evidence and a non-trivial oncologic caveat.

Best for

Recognizing a real endogenous mitochondrial signal whose promise is preclinical and observational, not an evidenced human energy therapy

Pricing

Research-use-only reagent; no legal human-use pathway

Source: Yen et al., Aging 2020 (PMC7343442)

This entry covers the broader mitochondrial-derived-peptide (MDP) axis — the coordinated retrograde-signaling system of MOTS-c, humanin and the six small humanin-like peptides (SHLP1–6), all encoded within mitochondrial rRNA genes and all declining with age. The axis framing is the most directly bioenergetic of the MDP concepts, but it is also the least clinically mature. There is nothing interventional in humans: no SHLP has been tested in any human efficacy trial, and the only human data are small, male-only serum studies showing SHLP2 is lower in obese and diabetic men and declines with age — correlation, not efficacy. Where the axis is most interesting is preclinical. SHLP2 binds respiratory complex I, increases oxygen-consumption rate and ATP, raises mtDNA copy number and the biogenesis regulator PGC-1α, and reduces ROS and apoptosis in cell models; in high-fat-diet mice it improved glucose tolerance and energy expenditure and activated brown-fat thermogenesis via hypothalamic POMC neurons. Together with MOTS-c (AMPK/biogenesis) and humanin (anti-apoptotic preservation), the MDPs form a plausible, multi-node mitochondrial-fitness network — entirely at the preclinical level. A critical caveat is heterogeneity: the SHLPs are not uniform. SHLP2 and SHLP3 are cytoprotective, SHLP4 is proliferative, and SHLP6 is pro-apoptotic and induces cell death. 'SHLP' is not one drug with one effect, so claims must be member-specific. There is no human dose for any SHLP, no human toxicology, and theoretical oncologic and angiogenic concerns from chronic receptor signaling, plus the standard unregulated-product contamination risk. Grade C across the board — the most mechanistically mitochondrial of the candidates and a coherent biogenesis concept, but one to two maturity tiers behind even MOTS-c. A research direction, not a therapy.

Best for

Recognizing the most mechanistically 'mitochondrial' concept in the category — and why it remains a preclinical research direction, not a therapy

Pricing

Research-use-only reagents; no legal human-use pathway

Source: Cobb et al., Aging 2016 (PMC4925829)

This entry is included as context, not as a peptide recommendation, because it defines the evidence bar the injectables have not cleared. From a functional-medicine, root-cause standpoint, the most defensible interventions for mitochondrial energy remain the unglamorous upstream ones — and they are backed by far stronger human evidence than any peptide here. Exercise is the standout: in humans it induces roughly a 12-fold rise in skeletal-muscle MOTS-c and raises humanin, meaning the endogenous mitochondrial-derived peptides that the injectables try to mimic are elevated by training itself, durably and safely. The causality runs the way the peptide marketing reverses it: exercise raises MOTS-c, not the other way around. Beyond training, the evidence-based levers are sleep, correcting genuine nutrient and hormonal deficiencies, reducing toxic load, and treating diagnosed mitochondrial disease through specialist care. None of this is exotic, and none carries the immunogenicity, impurity, tumor-promotion or anti-doping risks of unregulated peptides. The point of including exercise here is deliberate: when people ask which peptide will 'fix their mitochondria,' the honest comparison is that the single intervention with the strongest human evidence for raising mitochondrial-peptide signaling and improving cellular energy is not a peptide at all. Grade A — not because it is a drug, but because the human evidence for exercise-driven mitochondrial improvement is robust, reproducible and safe, which is exactly the standard the peptide candidates have not met.

Best for

Anchoring expectations: the intervention with the best human evidence for mitochondrial energy is exercise and upstream care, not an injectable peptide

Pricing

Free; no product required

Source: Reynolds et al., Nat Commun 2021